HCPLive Network
PERSONAL FINANCE

Celgene Sell Off “Overdone”

Laura Joszt | Friday, June 22, 2012
While Onyx Pharmaceuticals is flying high on good news for its blood cancer drug, Celgene wasn’t quite so lucky. Celgene’s stock took a big hit on Thursday when it withdrew its application for Revlimid. And by the end of the week, the stock hadn’t recovered much.
 
When the European Medicine’s Agency (EMA) indicated it wanted more data on Revlimid’s application to be used on newly diagnosed multiple myeloma patients and as a maintenance therapy, Celgene withdrew the application. When news broke, its stock dropped 11.65% at the opening bell on Thursday.
 
By the end of the day Friday, the stock had only recovered slightly, up 3.68%, but still down by 8.19% over where it had closed on Wednesday afternoon.
 
 
However, investors might be a little trigger happy with Celgene. For one, the company could still resubmit to EMA. Also, a trial combining Onyx’s Kyprolis with Revlimid and Dexa revealed that patients had a 98% response rate and a 92% progression-free survival rate.
 
Revlimid is already an approved blood cancer drug — the company is simply looking to expand its use. Plus, the drug could also have a number of other uses, such as lymphoma and CLL. Another Celgene drug could be approved for a second use this year.
 
According to SeekingAlpha, the sell off could nicely benefit investors who take advantage of it to buy up shares. Robert W. Baird released a note that it believed the sell off was overdone. The wealth management company has set a price target at $78.
 
The information contained in this article should not be construed as investment advice or as a solicitation to buy or sell any stock.
 
Read more:


RELATED ARTICLES
Most Americans know that a given medical service could cost a significantly different amount depending on where one receives the service, but only recently have cost data about healthcare charges become widely available and widely discussed. National Nurses United earlier this year evaluated US hospitals to find out how much they charge for a procedure versus the actual cost of performing the procedure.
If you somehow managed to avoid the 5 worst trading days each year, you could have earned a staggeringly high return on your investments. Here are a list of other surprising figures that could have a significant impact on your wallet.
There are cycles to markets and no one really knows when a small hiccup or a seismic shift may occur. Although the market over the past weeks has rattled some investors, the advice from advisors seems to be hold your course and do not do anything rash.
RECENT CLINICAL ARTICLES
For patients diagnosed with osteoarthritis, daily activities that many people take for granted, including sleep, can be interrupted or difficult, often causing psychological challenges as well.
The use of bone morphogenetic protein is not associated with operative nonunion rates after spinal fusion, according to a study published in the Oct. 15 issue of Spine.
A learning model and discussion can improve residents' attitudes and communication skills towards patients with substance abuse disorders, according to a study published online Oct. 7 in Academic Medicine.